Skip to main content

Table 1 Demographic data of the participants

From: Effectiveness and safety of tafluprost in primary open-angle glaucoma and ocular hypertension: a post-marketing phase IV study in China

Item

All (N = 285)

Group A (N = 165)

Group B (N = 89)

Group C (N = 31)

P

Age (y)

44.5 ± 16.1

43.7 ± 16.0

45.3 ± 17.1

46.5 ± 13.3

0.456

Sex

    

0.099

 Male

188 (66.0%)

117 (70.9%)

54 (60.7%)

17 (54.8%)

 

 Female

97 (34.0%)

48 (29.1%)

35 (39.3%)

14 (45.2%)

 

Ethnicity

    

0.248

 Han Chinese

277 (97.2%)

160 (97.0%)

88 (98.9%)

29 (93.5%)

 

 Others

8 (2.8%)

5 (3.0%)

1 (1.1%)

2 (6.5%)

 

With concomitant disease

142 (49.8%)

82 (49.7%)

47 (52.8%)

13 (41.9%)

0.580

Have concomitant medication

127 (44.6%)

7 (4.2%)

89 (100.0%)

31 (100.0%)

 < 0.001

Current diagnosis

    

0.076

 POAG

227 (79.6%)

136 (82.4%)

71 (79.8%)

20 (64.5%)

 

 OH

58 (20.4%)

29 (17.6%)

18 (20.2%)

11 (35.5%)

 

Course of disease (days)

    

 < 0.001

 N (Nmiss)

232 (53)

154 (11)

58 (31)

20 (11)

 

 Mean ± SD

255.7 ± 786.6

101.6 ± 634.3

502.1 ± 733.8

728.1 ± 1433.7

 

Eye using the study drug

    

0.221

 Right only

21 (7.4%)

8 (4.8%)

10 (11.2%)

3 (9.7%)

 

 Left only

11 (3.9%)

7 (4.2%)

2 (2.2%)

2 (6.5%)

 

 Both

253 (88.8%)

150 (90.9%)

77 (86.5%)

26 (83.9%)

 

Target eye

     

 Right

182 (63.9%)

101 (61.2%)

61 (68.5%)

20 (64.5%)

 

 Left

103 (36.1%)

64 (38.8%)

28 (31.5%)

11 (35.5%)

 

Baseline IOP (mmHg)

22.0 ± 4.2

22.4 ± 4.7

21.0 ± 3.5

22.5 ± 3.2

 
  1. POAG Primary open-angle glaucoma, OH Ocular hypertension, IOP Intraocular pressure